Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $28.00. The company’s shares closed last Tuesday at $14.52.
According to TipRanks.com, Yang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.5% and a 28.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Xeris Pharmaceuticals, and Eloxx Pharmaceuticals.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $27.00, an 89.1% upside from current levels. In a report issued on August 27, Needham also assigned a Buy rating to the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
Based on Aerie Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $27.19 million and GAAP net loss of $38.69 million. In comparison, last year the company earned revenue of $18.03 million and had a GAAP net loss of $48.19 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Read More on AERI:
